Almost Three-Quarters of Antiretrovirals Covered by Medicare Part D Had List Price Increases Above Inflation Between 2016 and 2017
Three-quarters of Part D ARVs Had Price Increases Above Inflation Download…
View the Latest: Prescription Drugs
Filter
-
-
Most Antiretrovirals Covered by Medicare Part D (as of 2017) Are Brand-Name, Single Source Medications
FeatureMost ARVs Covered by Medicare Part D are Brand Single Source Download…
-
Management and Delivery of the Medicaid Pharmacy Benefit
Issue BriefStates are limited in their leverage when it comes to controlling drug spending and use a variety of strategies to manage utilization, including an increased reliance on managed care and pharmacy benefit managers (PBMs). As policymakers debate proposals that include provisions related to Medicaid pharmacy benefits, it is important to understand the challenges state Medicaid programs face and how policy proposals may impact Medicaid beneficiaries and costs.
-
KFF Health Tracking Poll – November 2019: Health Care In The 2020 Election, Medicare-for-all, And The State Of The ACA
FeatureThis poll examines the issues Democrats most want to hear in the debates, their trust of the Democratic candidates on health care, attitudes towards Medicare-for-all and a public option, perceptions of the Affordable Care Act's health insurance marketplaces, and prospects of legislation to address prescription drug costs.
-
Medicare Part D: A First Look at Medicare Prescription Drug Plans in 2021
Issue BriefThis issue brief provides an overview of the Medicare Part D prescription drug benefit plan landscape for 2021, with a focus on stand-alone drug plans. It includes national and state-level data on plan availability, premiums, benefit design, cost sharing, information about premium-free plans for low-income beneficiaries, and information about the national Part D drug plans available in 2021.
-
How Would Drug Price Negotiation Affect Medicare Part D Premiums?
Issue BriefProposals to allow the federal government to negotiate prescription drug prices, such as H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, aim to lower out-of-pocket drug costs for Medicare beneficiaries and private plan enrollees and achieve savings for Medicare. This data note estimates average premium savings attributable to the negotiations provision of H.R. 3 on a per capita basis for Part D enrollees who pay premiums in dollar amounts and as a share of the base beneficiary premium, based on aggregate premium reductions and baseline premiums projected by Medicare’s actuaries through 2029.
-
Millions of Medicare Part D Enrollees Have Had Out-of-Pocket Drug Costs High Enough to Exceed the Catastrophic Threshold Over Time
News ReleaseNearly 3 million Medicare Part D enrollees had out-of-pocket drug spending above the catastrophic threshold in a recent five-year period, finds a new KFF analysis that takes a comprehensive look at how many people on Medicare have drug expenses high enough to push them above that limit.
-
KFF Health Tracking Poll – January 2020: Medicare-for-all, Public Option, Health Care Legislation And Court Actions
FeatureThis month's KFF Health Tracking poll examines public opinion and knowledge of Medicare-for-all and a public option, President Trump's approval on health care programs and issues, the public's priorities for Congress, and public opinion on the Affordable Care Act and the Texas v. U.S. court case.
-
Among the Most Commonly Used Antiretrovirals Covered by Part D in 2017, 9 of 10 Had List Prices Exceeding Inflation
Feature9 of 10 Most Commonly Used ARVs in Part D Had List Prices Above Inflation Download…
-
Potential Savings for Medicare Part D Enrollees Under Proposals to Add a Hard Cap on Out-of-Pocket Spending
Issue BriefMedicare Part D, the outpatient prescription drug benefit for Medicare beneficiaries, provides coverage above a catastrophic threshold for high out-of-pocket drug costs, but there is no cap on total out-of-pocket drug costs that beneficiaries pay each year. Recent legislative proposals would add a cap on out-of-pocket spending under Part D. This analysis focuses on the potential impact of different out-of-pocket spending caps in terms of how many beneficiaries would be affected and how much they could save.